{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T07:09:26Z","timestamp":1769324966877,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,4,30]],"date-time":"2012-04-30T00:00:00Z","timestamp":1335744000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2012,4,30]],"date-time":"2012-04-30T00:00:00Z","timestamp":1335744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>The aim of this study was to investigate the effect of three years of tumor necrosis factor-alpha (TNF-\u03b1) blocking therapy on bone turnover as well as to analyze the predictive value of early changes in bone turnover markers (BTM) for treatment discontinuation in patients with ankylosing spondylitis (AS).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>This is a prospective cohort study of 111 consecutive AS outpatients who started TNF-\u03b1 blocking therapy. Clinical assessments and BTM were assessed at baseline, three and six months, as well as at one, two, and three years. Z-scores of BTM were calculated to correct for age and gender. Bone mineral density (BMD) was assessed yearly.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>After three years, 72 patients (65%) were still using their first TNF-\u03b1 blocking agent. In these patients, TNF-\u03b1 blocking therapy resulted in significantly increased bone-specific alkaline phosphatase, a marker of bone formation; decreased serum collagen-telopeptide (sCTX), a marker of bone resorption; and increased lumbar spine and hip BMD compared to baseline. Baseline to three months decrease in sCTX Z-score (HR: 0.394, 95% CI: 0.263 to 0.591), AS disease activity score (ASDAS; HR: 0.488, 95% CI: 0.317 to 0.752), and physician's global disease activity (HR: 0.739, 95% CI: 0.600 to 0.909) were independent inversely related predictors of time to treatment discontinuation because of inefficacy or intolerance. Early decrease in sCTX Z-score correlated significantly with good long-term response regarding disease activity, physical function and quality of life.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Three years of TNF-\u03b1 blocking therapy results in a bone turnover balance that favors bone formation, especially mineralization, in combination with continuous improvement of lumbar spine BMD. Early change in sCTX can serve as an objective measure in the evaluation of TNF-\u03b1 blocking therapy in AS, in addition to the currently used more subjective measures.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar3823","type":"journal-article","created":{"date-parts":[[2012,4,30]],"date-time":"2012-04-30T16:15:27Z","timestamp":1335802527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study"],"prefix":"10.1186","volume":"14","author":[{"given":"Suzanne","family":"Arends","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneke","family":"Spoorenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieternella M","family":"Houtman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha K","family":"Leijsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Bos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cees GM","family":"Kallenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk","family":"Groen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline","family":"van der Veer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,30]]},"reference":[{"key":"3573_CR1","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/art.20990","volume":"52","author":"M Rudwaleit","year":"2005","unstructured":"Rudwaleit M, Khan MA, Sieper J: The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. Arthritis Rheum. 2005, 52: 1000-1008. 10.1002\/art.20990.","journal-title":"Arthritis Rheum"},{"key":"3573_CR2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1136\/ard.2006.066415","volume":"66","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, Braun J: Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007, 66: 910-915. 10.1136\/ard.2006.066415.","journal-title":"Ann Rheum Dis"},{"key":"3573_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/BOR.0b013e328133f5b3","volume":"19","author":"P Geusens","year":"2007","unstructured":"Geusens P, Vosse D, van der Linden S: Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol. 2007, 19: 335-339. 10.1097\/BOR.0b013e328133f5b3.","journal-title":"Curr Opin Rheumatol"},{"key":"3573_CR4","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/ard.2008.100503","volume":"68","author":"D Vosse","year":"2009","unstructured":"Vosse D, Landewe R, van der Heijde D, van der Linden S, van Staa TP, Geusens P: Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis. 2009, 68: 1839-1842. 10.1136\/ard.2008.100503.","journal-title":"Ann Rheum Dis"},{"key":"3573_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00198-010-1338-7","volume":"22","author":"S Arends","year":"2011","unstructured":"Arends S, Spoorenberg A, Bruyn GA, Houtman PM, Leijsma MK, Kallenberg CG, Brouwer E, van der Veer E: The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int. 2011, 22: 1431-1439. 10.1007\/s00198-010-1338-7.","journal-title":"Osteoporos Int"},{"key":"3573_CR6","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/art.24001","volume":"59","author":"J Braun","year":"2008","unstructured":"Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D: Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008, 59: 1270-1278. 10.1002\/art.24001.","journal-title":"Arthritis Rheum"},{"key":"3573_CR7","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3899\/jrheum.081033","volume":"36","author":"B Dijkmans","year":"2009","unstructured":"Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L, Salvarani C, Sanmarti R, Sibilia J, Sieper J, van den Bosch F, van der Heijde D, van der Linden S, Wajdula J: Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol. 2009, 36: 1256-1264. 10.3899\/jrheum.081033.","journal-title":"J Rheumatol"},{"key":"3573_CR8","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1136\/ard.2007.087270","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC: Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis. 2009, 68: 922-929. 10.1136\/ard.2007.087270.","journal-title":"Ann Rheum Dis"},{"key":"3573_CR9","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1136\/ard.2004.033472","volume":"64","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J: Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis. 2005, 64: 1462-1466. 10.1136\/ard.2004.033472.","journal-title":"Ann Rheum Dis"},{"key":"3573_CR10","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC: Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008, 58: 1324-1331. 10.1002\/art.23471.","journal-title":"Arthritis Rheum"},{"key":"3573_CR11","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R: Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009, 11: R127-10.1186\/ar2794.","journal-title":"Arthritis Res Ther"},{"key":"3573_CR12","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1136\/ard.2009.124446","volume":"69","author":"B Glintborg","year":"2010","unstructured":"Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML: Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010, 69: 2002-2008. 10.1136\/ard.2009.124446.","journal-title":"Ann Rheum Dis"},{"key":"3573_CR13","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/acr.20258","volume":"62","author":"LE Kristensen","year":"2010","unstructured":"Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P: Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken). 2010, 62: 1362-1369. 10.1002\/acr.20258.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3573_CR14","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar3369","volume":"13","author":"S Arends","year":"2011","unstructured":"Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Jansen TL, Kallenberg CG, Spoorenberg A: Baseline predictors of response and discontinuation of TNF-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011, 13: R94-10.1186\/ar3369.","journal-title":"Arthritis Res Ther"},{"key":"3573_CR15","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Lie E, Kvien TK, Sieper J, van den Bosch F, Listing J, Braun J, Landewe R: ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009, 68: 1811-1818. 10.1136\/ard.2008.100826.","journal-title":"Ann Rheum Dis"},{"key":"3573_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D: Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009, 68: 18-24.","journal-title":"Ann Rheum Dis"},{"key":"3573_CR17","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/rheumatology\/ker087","volume":"50","author":"M Xu","year":"2011","unstructured":"Xu M, Lin Z, Deng X, Li L, Wie Y, Liao Z, Li Q, Wie Q, Hu Z, Zhang Y, Lin Q, Huang J, Li T, Pan Y, Wu Y, Jin O, Yu B, Gu J: The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-{alpha} inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China. Rheumatology (Oxford). 2011, 50: 1466-1472. 10.1093\/rheumatology\/ker087.","journal-title":"Rheumatology (Oxford)"},{"key":"3573_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA: Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011, 22: 391-420. 10.1007\/s00198-010-1501-1.","journal-title":"Osteoporos Int"},{"key":"3573_CR19","first-page":"1753","volume":"34","author":"JH Woo","year":"2007","unstructured":"Woo JH, Lee HJ, Sung IH, Kim TH: Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol. 2007, 34: 1753-1759.","journal-title":"J Rheumatol"},{"key":"3573_CR20","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/ar2537","volume":"10","author":"H Appel","year":"2008","unstructured":"Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J: Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther. 2008, 10: R125-10.1186\/ar2537.","journal-title":"Arthritis Res Ther"},{"key":"3573_CR21","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/ard.2010.138883","volume":"70","author":"SJ Pedersen","year":"2011","unstructured":"Pedersen SJ, Sorensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Moller J, Hasselquist M, Mikkelsen D, Skjodt T, Lambert R, Hansen A, Ostergaard M: ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF\u03b1 inhibitors. Ann Rheum Dis. 2011, 70: 1375-1381. 10.1136\/ard.2010.138883.","journal-title":"Ann Rheum Dis"},{"key":"3573_CR22","first-page":"2030","volume":"35","author":"WP Maksymowych","year":"2008","unstructured":"Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GT, Ballal S, Wong RL, Inman RD: Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol. 2008, 35: 2030-2037.","journal-title":"J Rheumatol"},{"key":"3573_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/ard.2007.084426","volume":"68","author":"S Visvanathan","year":"2009","unstructured":"Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J: Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis. 2009, 68: 175-182. 10.1136\/ard.2007.084426.","journal-title":"Ann Rheum Dis"},{"key":"3573_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984, 27: 361-368. 10.1002\/art.1780270401.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"3573_CR25","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landewe R, Maksymowych W, van der Heijde D: The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009, 68 (Suppl 2): ii1-44. 10.1136\/ard.2008.104018.","journal-title":"Ann Rheum Dis"},{"key":"3573_CR26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/ard.2011.151563","volume":"70","author":"D van der Heijde","year":"2011","unstructured":"van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, Rudwaleit M, Braun J: 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011, 70: 905-908. 10.1136\/ard.2011.151563.","journal-title":"Ann Rheum Dis"},{"key":"3573_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994, 4: 368-381. 10.1007\/BF01622200.","journal-title":"Osteoporos Int"},{"key":"3573_CR28","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1126\/science.3287615","volume":"240","author":"JA Swets","year":"1988","unstructured":"Swets JA: Measuring the accuracy of diagnostic systems. Science. 1988, 240: 1285-1293. 10.1126\/science.3287615.","journal-title":"Science"},{"key":"3573_CR29","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s100670050120","volume":"18","author":"ES Meirelles","year":"1999","unstructured":"Meirelles ES, Borelli A, Camargo OP: Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol. 1999, 18: 364-68. 10.1007\/s100670050120.","journal-title":"Clin Rheumatol"},{"key":"3573_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00296-004-0516-3","volume":"26","author":"HJ Baek","year":"2005","unstructured":"Baek HJ, Kang SW, Lee YJ, Shin KC, Lee EB, Yoo CD, eSong YW: Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int. 2005, 26: 30-34. 10.1007\/s00296-004-0516-3.","journal-title":"Rheumatol Int"},{"key":"3573_CR31","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC: Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008, 58: 1324-1331. 10.1002\/art.23471.","journal-title":"Arthritis Rheum"},{"key":"3573_CR32","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Williamson P, Xu W, Baker D, Goldstein N, Braun J: Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008, 58: 3063-3070. 10.1002\/art.23901.","journal-title":"Arthritis Rheum"},{"key":"3573_CR33","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, Ballal S, Gbison E, Wong R: Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009, 11: R127-10.1186\/ar2794.","journal-title":"Arthritis Res Ther"},{"key":"3573_CR34","first-page":"855","volume":"35","author":"K Briot","year":"2008","unstructured":"Briot K, Gossec L, Kolta S, Dougados M, Roux C: Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiver anti-tumor necrosis factor-\u03b1 treatment. J Rheumatol. 2008, 35: 855-861.","journal-title":"J Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3823.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar3823\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3823.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:31:21Z","timestamp":1728383481000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar3823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,30]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,4]]}},"alternative-id":["3573"],"URL":"https:\/\/doi.org\/10.1186\/ar3823","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,30]]},"assertion":[{"value":"9 February 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R98"}}